# A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

> **NCT05918133** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biotheus Inc.** · enrollment: 42 (actual)

## Conditions studied

- TNBC

## Interventions

- **DRUG:** PM8002
- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT05918133
- **Lead sponsor:** Biotheus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918133, "A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT05918133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*